Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Erythromycin

FDA-approved product (ointment, ophthalmic), marketed as A/T/S, Akne-Mycin, C-Solve-2 and 34 more.

Registered studies
50+
Lab records
32
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Erythromycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Bacterial disease
  • Eye infection
  • Infection
  • Whooping cough

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiinfectives for treatment of acne; Macrolides; Antibiotics
FDA pharmacologic class
Macrolide; Macrolide Antimicrobial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC D10AF02; WHO ATC D10AF52; WHO ATC J01FA01; WHO ATC S01AA17

Repurposing investigation

Erythromycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA28.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli3.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae52.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis71.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 17 of 25 lab records
  • E. coli: measured active in 0 of 1 lab record
  • K. pneumoniae: measured active in 6 of 6 lab records
Open Erythromycin in ChEMBL Registered studies below
Show the 32 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Erythromycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Clarithromycin 500 mg Tablets Under Non-Fasting Conditions

    NCT00836706 · start 2002-07

    Registered record
    Registry ID
    NCT00836706
    Conditions
    Healthy
    Interventions
    clarithromycin; BIAXIN®
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2002-07
    Completion
    2002-07
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionclarithromycin; BIAXIN®
    PhasePhase 1
    Registry statusCompleted

  • Risk of Acute Liver Injury in Users of Antimicrobials

    NCT01434173 · start 2001-07

    Registered record
    Registry ID
    NCT01434173
    Conditions
    Drug-Induced Liver Injury
    Interventions
    Moxifloxacin (Avelox, BAY12-8039); Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2001-07
    Completion
    2009-03
    Enrolment
    1,299,056

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-Induced Liver Injury
    InterventionMoxifloxacin (Avelox, BAY12-8039); Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
    PhaseNot recorded
    Registry statusCompleted

  • Azithromycin/Bicillin Syphilis

    NCT00031499 · start 2000-06

    Registered record
    Registry ID
    NCT00031499
    Conditions
    Syphilis
    Interventions
    Azithromycin; Benzathine Penicillin; Doxycycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-06
    Completion
    2009-03
    Enrolment
    593

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSyphilis
    InterventionAzithromycin; Benzathine Penicillin; Doxycycline
    PhasePhase 3
    Registry statusCompleted

  • Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer

    NCT00148070 · start 1999-03

    Registered record
    Registry ID
    NCT00148070
    Conditions
    Metastatic Breast Cancer
    Interventions
    Docetaxel; Erythromycin Breath Test (ERMBT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-03
    Completion
    2006-02
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionDocetaxel; Erythromycin Breath Test (ERMBT)
    PhasePhase 2
    Registry statusCompleted

  • Azithromycin Combination Therapy for Malaria

    NCT00299208

    Registered record
    Registry ID
    NCT00299208
    Conditions
    Plasmodium Falciparum Malaria
    Interventions
    Artesunate; Azithromycin; Quinine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2005-07
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlasmodium Falciparum Malaria
    InterventionArtesunate; Azithromycin; Quinine
    PhasePhase 2
    Registry statusCompleted